Why is ENTA down?
Down 34% from Nov 11 to Nov 20 while the S&P 500 fell 9%.
“The decrease in the quarter and year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET/MAVIRET.”
−3Long-term trend
Down 34% from Nov 11 to Nov 20 while the S&P 500 fell 9%.
“The decrease in the quarter and year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET/MAVIRET.”
−3Long-term trend
Follow ENTA's trial news. Pro members can get an alert when Enanta Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Sales down 20% |
| Latest filing | 10-K, Nov 18 |
Wed Dec 2: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.
Expected to report Mon Feb 8, after the close
The company says its cash lasts into Fiscal 2029 (8-K, Nov 16).
An officer, Kathleen S. Capps, sold 323 shares on Dec 5, 2025.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ENTA is #261 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 261 |
Expected to report Mon Feb 8, after the close (in 79 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $12.9M, 15% less than a year ago; a loss of $0.81 a share, from $0.87.
“The decrease in the quarter and year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET®/MAVIRET®.”
ENTA's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase in the quarter and year-over-year interest expense was due to an increase in forecasted royalty revenue from AbbVie’s net sales of MAVYRET®/MAVIRET® during the first half of Enanta’s 2026 fiscal year.”
From its results filing (SEC filing · Nov 16)
Sales fell 8.3% a year over 5 years, fiscal 2021 to 2026.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 16, 2026 | -3.9% | -18.6% | not yet |
| Aug 10, 2026 | -0.5% | -2.1% | -7.1% |
| May 11, 2026 | -5.6% | -6.0% | -13.0% |
Sales fell every year from 2019 to 2026, to $63M. It made a profit in one of the eight years.
RSI 25.3, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ENTA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Enanta Pharmaceuticals Inc is a biotechnology company that uses its robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs with an emphasis on viral infections and immunological diseases. The company has single operating segment.
“We are engaged in segments of the pharmaceutical industry that are highly competitive and rapidly changing.”
ENTA scores -10 today, which Breakaway calls Poor. It is #261 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 34% from Nov 11 to Nov 20 while the S&P 500 fell 9%. Shares: 35.9% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ENTA scores -10 today, which Breakaway calls Poor (below zero). That is #261 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ENTA's -10.
Expected to report Mon Feb 8, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ENTA closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.